Skip to content

Anti-Dandruff activity of 5 percent Foligen SeboBalance Serum

A Clinical Study to Evaluate the Anti-Dandruff activity of 5 percent Foligen SeboBalance Serum - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112153
Enrollment
32
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: 5% Foligen SeboBalance Serum: Test Product: 5% Foligen SeboBalance Serum Dose:3-4 sprays thrice a week before washing hair with any shampoo Route of Administration: Topica

Sponsors

GFCP Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Gender: Non-pregnant, non-lactating female aged between 18 to 45 2.Subject with Dandruff 3.Subject willing to give written informed consent 4.Women of child bearing potential must have a negative urine pregnancy test 5.Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. 6.Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study

Exclusion criteria

Exclusion criteria: 1.Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2.Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 3.Have open sore or open lesions in the treatment area 4.Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 5.Have participated in any interventional clinical trial in the previous 30 days. 6.Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 7.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. 8.Have undergone any hair treatments (such as chemical straightening, coloring, perming, or other salon-based procedures) within 30 days prior to enrollment in the study. 9.Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

MeasureTime frame
1.Change in Scalp Dryness 2.Change in Scalp Sebum 3.Change in Dandruff (Flaking) 4.Dermascopy ImagingTimepoint: At Day0 and Day 7

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026